Continuing Access to Critical Medications Post-Approval
McHade offers Post-Approval Named Patient Programs (NPPs) that ensure patients continue receiving life-saving treatments even after clinical trials are completed but before full commercial availability. We manage the regulatory and logistical complexities to provide access to medications for patients in need.
Comprehensive Solutions for Named Patient Programs
Our Aim is to Provide Continued Access to Medications Post-Approval
McHade is committed to ensuring that patients continue to receive essential medications after clinical trials but before full market availability. We streamline the process of obtaining regulatory approvals and coordinating global distribution to deliver life-saving therapies to patients as part of our Post-Approval Named Patient Programs.
Frequently Asked Questions About Specialty Drug Access
What is a Named Patient Program (NPP)?
An NPP allows patients to access post-approval medications that are not yet commercially available in their country but have been approved elsewhere.
How does McHade manage regulatory requirements for NPPs?
Our regulatory experts navigate the complex post-approval landscape, ensuring compliance with local and international laws so that patients can receive medications safely.
Who qualifies for a Named Patient Program?
Patients with serious conditions, who require treatment with post-approval medications that are not yet available commercially, may qualify for NPPs.
How do you ensure medications are delivered in a timely manner?
We work with trusted global logistics partners, utilizing real-time tracking and monitoring to ensure that medications are delivered on time, no matter the location.
Can NPPs be tailored to specific markets or patient needs?
Yes, we customize each NPP to meet the unique regulatory, logistical, and patient needs of each market, ensuring seamless access.